


# DIGNITANA

*Clinically superior scalp cooling*

NOVEMBER 21 • 2024



## Q3 24

## More progress in reimbursement

QUARTERLY REPORT

## More progress in reimbursement

### Financial highlights Q3 2024

- Net Sales amounted to 22.8 MSEK (22.2), an increase of 3 percent over the same quarter in 2023.
- Operating Result amounted to -0.7 MSEK (-3.2).
- Net Result after financial items amounted to -1.5 MSEK (-3.7).
- EBITDA for the third quarter is positive at 2.1 MSEK (0.7).
- Earnings per share were -0.02 SEK (-0.05).
- Cash Balance amounted to 4.4 MSEK (7.0).
- Average Daily Treatment Revenue (ADTR)\* was 231 TSEK (237) in the quarter.

” *Transformation is necessary, because only if we can create growth and profitability will we truly be able to live up to our purpose.*

– Fredrik Jonsson, CEO

### Business highlights during the period

- In August Dignitana leadership and Board members completed several PDMR transactions. Dignitana CEO Fredrik Jonsson purchased 50,000 shares, Chairman of the Board of Directors Klas Arildsson purchased 50,000 shares, and Board member Fredrik Lindgren purchased 143,511 shares.

### Business highlights after the period

- Dignitana Board member Fredrik Lindgren completed a PDMR transaction in October purchasing 1,500,000 shares.
- In October Dignitana expanded the company's partnership with InfuSystem Holdings, Inc. to include field service support of DigniCap in U.S. chemotherapy infusion centers, providing rapid and enhanced support to customers.
- Later that month the American Medical Association (AMA) issued three new CPT® Category I codes for scalp cooling that will become effective January 2026. The issuance of these permanent elevated codes is a significant milestone for the company that will result in increased reimbursement for providers and improved financial access for patients.
- In November the US Centers for Medicare & Medicaid Services (CMS) published the OPPS Final Rule with a 40 percent increase in the average rate for CPT® 0662T over the 2024 amount, providing greater financial support for Medicare-eligible patients.
- University Hospital Schleswig-Holstein in Kiel, Germany (UKSH) purchased two DigniCap Delta devices and began offering scalp cooling to their patients in October.
- In November the The Aleris Oncology Clinic at Sabbatsberg Hospital, Stockholm expanded access to scalp cooling for patients in Sweden. Aleris purchased a DigniCap Delta device after completing a successful pilot evaluation of scalp cooling at Aleris Christinakliniken.

### Key Figures

DIGNITANA GROUP	Q3 2024	Q3 2023	Q1-Q3 2024	Q1-Q3 2023	FY 2023
Net sales, TSEK	22,849	22,219	65,858	64,797	86,063
Total revenues, TSEK	23,077	22,345	66,411	67,109	89,025
Net profit after financial items, TSEK	-1,547	-3,685	-18,057	-12,285	-17,228
Cash and bank balances, TSEK	4,448	6,961	4,448	6,961	6,027
Earnings per share, SEK	-0.02	-0.05	-0.24	-0.17	-0.25
Average Daily Treatment revenue, TSEK	231	237	231	240	239

\* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA'S VISION IS TO ENSURE THAT CANCER PATIENTS CAN MAINTAIN DIGNITY AND QUALITY OF LIFE DURING AND AFTER CANCER TREATMENT.

## More progress in reimbursement

We leave behind a quarter characterized by hard work, and we see that the necessary and strategic changes are gradually beginning to bear fruit. Our corporate culture firmly embodies the aim of preserving a patient's dignity during a difficult situation. Still, there are challenges in our aim to offer scalp cooling. Challenges that must be met by constantly being open to change and preparing for new market conditions and customer needs. Transformation is necessary, because only if we can create growth and profitability will we truly be able to live up to our purpose.

Our management team is focused on strategic priorities that drive profitability. We are simultaneously launching several key initiatives, including fine-tuning our organization and optimizing our sales efforts while keeping costs minimal. In essence, our focus is on optimizing our approach to achieve better results.

In October, we announced a field service partnership with InFuSystem to enhance customer support. After training and a two-month pilot, they will take over the service function from our staff. We anticipate both increased patient treatment volume and even higher customer satisfaction once customers have access to rapid response field service that virtually eliminates downtime. The new partnership with InFuSystem will provide time to accelerate sales efforts and enable us to work more efficiently, while at the same time lowering fixed costs. We are also diligently identifying other functions that would benefit from an outsourcing solution or a partnership.

The US continues to be the primary market for DigniCap. As awareness for scalp cooling increases, we will continue to grow. Anticipating building competition and evolving market needs, we are proactively expanding our business model portfolio to capitalize on increasing awareness of our solution.

In the coming months we will fine-tune our business models to address a variety of customer needs, whether it is an individual clinic, large group of providers or an academic hospital. During the past quarter we have met with customers in over twenty metropolitan areas to listen to customer needs and introduce a more individual and tailored offering to meet the specific needs of the practice.


In October, we reached a significant milestone in our long-term reimbursement efforts. An updated AMA code set will take effect as of 2026. Category I codes are the gold standard in reimbursement and provide a clear pathway to coverage and payment for DigniCap providers. This will provide greater financial accessibility for patients and increase utilization of scalp cooling. In short, we are approaching a new reimbursement environment with greater access and affordability for patients as well as more stable and predictable market conditions.

Parallel to our efforts in the US, we have increased our presence in several other important markets, and we see a higher frequency of inquiries as well. During the third quarter, we have had a follow up visit with our partner Konica Minolta in Japan. We have also performed training sessions in Europe, where we now have announced new orders from Sweden and Germany. Despite the summer months and lower activity in the market, we see an increase in our customer base and sales are up three percent in the quarter.

I want to end by thanking our shareholders for the ongoing support of our mission, and our co-workers for staying focused on Dignitana's purpose while being open-minded to embrace new ideas and approaches. With several strategic initiatives underway, we are making progress towards greater opportunities, growth and profitability.



# Dignitana through the years



**32 countries**  
**260+ centers in US**

- 1970s** ● Patients worldwide begin manual scalp cooling with ice packs
- 1996** ● Swedish nurse Yvonne Olofsson invents DigniCap scalp cooling device
- 2001** ● DigniCap C2 launched in Sweden
- 2009** ● DigniCap C3 launched in Europe, Australia & Latin America
- 2015** ● **June** – DigniCap Pivotal Trial presented at ASCO  
**December** – FDA clearance in US for female breast cancer patients using DigniCap
- 2017** ● **February** – JAMA publishes pivotal trial  
**July** – FDA clearance expanded for DigniCap use by men and women with all solid tumors
- 2019** ● **June** – DigniCap Delta FDA clearance  
**March** – DigniCap Delta CE Mark
- 2021** ● **March** – NCCN® treatment recommendations for Breast, Ovarian and other Gyn cancers  
**July** – CPT Codes for scalp cooling issued by AMA  
**September** – Cancer Australia adds scalp cooling to Guidance for Breast cancer  
**October** – ESMO adds scalp cooling as a category IIB recommendation for European patients
- 2022** ● **January** – Medicare rate assignment
- 2023** ● **November** – Palmetto MAC Local Coverage Determination for 7 states in US
- 2024** ● **February** – Konica Minolta signed as exclusive distributor for Japan
- Today** ● DigniCap available in over 32 countries and 260+ centers in US

# The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid


tumors in addition to the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta and the technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year.

Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.

# Business model

The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables. In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. Dignitana offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more standard, we

are transitioning providers to this model that is widely used in healthcare. Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



# Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible.

The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients. The Company has customized the Buy and Bill model to offer patients and providers flexibility in how they choose to pay for the service.

Since 2021 Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including proactive initiatives seeking the introduction of CPT® codes for

scalp cooling, annual rate assignments from the Centers for Medicare & Medicaid Services (CMS), and a Local Coverage Determination (LCD) from the Palmetto Medicare Administrative Contractor (MAC) for Medicare beneficiaries in seven states in the southeastern United States. Together these initiatives are increasing support for health care providers to receive reimbursement to administer FDA-cleared scalp cooling therapy, thereby increasing patient access to DigniCap.

Dignitana continues to work with commercial payers, Medicare and other MACs to advance reimbursement of scalp cooling and improve accessibility and affordability for patients with the long term goals of fair and reasonable reimbursement to providers as scalp cooling is established as standard of care.



# The market

## The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 20 million incidences of cancer diagnosed annually, with 2 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 311,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8–10 percent of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling.

## Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently.

The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



Pre chemo



During chemo

”

*It was extremely important that I saved my hair through scalp cooling. I was able to continue my usual activities and social life throughout the entire treatment, with most people not knowing anything about what I was going through! To me this was huge, uplifting, gave me the strength I needed.*

- Cristina, North Carolina



After chemo

# My hair was a part of my identity that I wanted to hold onto

I am Stephanie, a Relentless Pink Sister. I am 46, a wife, and a mother. I was diagnosed with breast cancer at 42 years young.


DigniCap was one of the tools used to attempt to keep my hair, and it was a success! I underwent four different aggressive chemotherapies, and while I did lose a lot of hair, I did not have a single bald spot! I was so impressed. Additionally, my hair grew back quite quickly.

Keeping my hair during chemotherapy was important to me because it was a way to maintain a sense of normalcy and control during an incredibly challenging and uncertain time. Chemotherapy can make you feel like you're losing so much—your health, your energy, and even parts of your identity. For me, my hair was a part of my identity that I wanted to hold onto. It symbolized more than just appearance; it was about feeling like myself, staying connected to my pre-diagnosis life, and showing up strong for my family and myself.

*It wasn't just about vanity—it was about maintaining a positive mindset, feeling empowered in the face of Cancer, and showing that There IS Life Beyond The Diagnosis.*

Additionally, I believed that if I could take measures to preserve my hair, it meant I was also protecting my overall health, which aligned with my holistic approach to healing.

Keeping my hair during chemotherapy, even though it was very thin and short, had a significant impact on myself and those around me. I highly recommend DigniCap to everyone!



**Stephanie | Louisiana**

**Age:** 46

**Diagnosis:** Invasive Triple Negative Breast Cancer, Stage III

**Chemotherapy Regimen:** Taxotere/Carboplatin and Adriamycin/Cytoxan

**Total Treatments:** 15

**Infusion Center:** Ochsner, New Orleans

*During chemo*



*4 months after chemo*



*1 year after chemo*





# Financial information and comments

## DIGNITANA GROUP

---

### Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the third quarter 2024 net sales amounted to 22,849 TSEK (22,219), an increase over the same period 2023 by 630 TSEK representing 3 percent. The U.S. market increased 5 percent during the quarter in local currency and the off set for currency adjustments were 4 percent.

Dignitana operates by two business models: in the U.S. DigniCap systems are leased to health care providers. The Company generates revenue from leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements as well as the sale of patient consumables.

The U.S. is the driver in placing DigniCap Delta on the market using the leasing business model. To facilitate a good usage of the assets, the Company focuses on reallocating less utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients with less investment and cost, improve patient outcomes, and thereby achieve higher growth. Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In Q3 2024 net exchange rate effects amounted to 214 TSEK (125).

### Operating Expenses and Operating Result

Operating expenses, including Personnel expenses but excluding depreciation, amortization and COGS, decreased during the third quarter compared to the same period last year by 1,553 TSEK and amounted to -12,951 TSEK (-14,504). The main reasons for the decrease are lower costs for external services and marketing activities during Q3. Depreciation and amortization in the Group amounted to -2,861 TSEK (-3,828) for the third quarter. Development costs for the DigniCap Delta system were fully depreciated during Q2 2024 and gives a lower total depreciation cost during Q3.

The operating result after depreciation for the Group for the third quarter 2024 was -730 TSEK (-3,154). Thereby EBITDA for the quarter is positive at 2,131 TSEK (674).

### Financial net

The financial net was -817 TSEK (-531) in Q3, mainly affected by debt-related interest and exchange effect on loans.

### Employees

At the close of the period the Company had 26 (27) employees.

### Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was 3,354 TSEK (-173). Total cash flow for the period was -2,298 TSEK (1,563). For the same period last year a loan of 5 MSEK was taken out. During the third quarter 2024 the company has sold out from Inventory and reduced Receivables from customers. Cash and cash equivalents at the end of the quarter amounted to 4,448 TSEK (6,961).

Considering the outcome for the last 12 months, current cash reserves may not cover ongoing spending a year ahead. However, cash flow from operating activities are improving over time and the Board of Directors are actively pursuing various alternatives to secure funding for ongoing business as well as forward-looking activities. The efforts include exploring debt financing, external financing and new investments. The Board of Directors is fully committed to ensure financial stability and success and will keep stakeholders informed as decisions are taken.

### CAPEX

Capex amounted to 1,016 TSEK (1,430) in the third quarter, mainly in tangible assets.

# The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

## Dignitana AB

TICKER	DIGN
Market Cap September 28	70 MSEK
Number of shareholders, approximately	2,055
Share price September 28	0.88 SEK
Number of shares traded during the quarter	3,561,954
Number of shares outstanding September 28	80,541,891
Registered share capital	8,054,189 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and at the general meeting in May 2023 a decision was taken to issue a maximum of 1,800,000 employee warrants to key employees of the Company. The period for the employee stock warrants runs from June 2023 to June 2026.

## Largest Shareholders

30 SEPTEMBER 2024	HOLDINGS	PERCENT
AGARTHA AB	24,000,000	29.80%
SWEDBANK ROBUR MICROCAP	6,188,571	7.68%
AVANZA PENSION	5,837,727	7.25%
UBS FNANCIAL SERVICES INC	4,189,739	5.20%
HANDELSBANKEN MICROCAP SVERIGE	3,050,286	3.79%
FÖRSÄKRINGSBOLAGET SKANDIA	2,745,999	3.41%
LQM LUNDIA AB	2,631,578	3.27%
MAGBALEO	2,000,000	2.48%
TECHNOVOBIS AB	1,790,593	2.22%
FCG FONDER AB	1,558,270	1.93%
<b>TOTAL</b>	<b>53,992,763</b>	<b>67.04%</b>
OTHER SHAREHOLDERS	26,549,128	32.96%
<b>TOTAL</b>	<b>80,541,891</b>	<b>100.00%</b>

Source: Euroclear



Before chemo



Last chemo

”

*I could look in the mirror and still be me. I looked the same as always, and this gave my family comfort that I was going to be okay.*

- Linda, Florida



After chemo

## Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment.

methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

### *Risks related to pandemics*

The outbreak of Covid-19 and the resulting restrictions have, for a long time to come, changed the conditions of most healthcare providers worldwide. The heavy workload in healthcare created a large staff turnover and forced new priorities and new work processes for both healthcare providers and suppliers, while the need for training increased. Together with the risks of new pandemic outbreaks and subsequent restrictions, this forces medical technology suppliers to be more flexible in their marketing and in their communication with customers. As an example of this, Dignitana has developed a portal through which patients and caregivers can receive training and information about the company's products and services digitally..

### *Risks related to military conflicts in the outside world*

The company's assessment is that the ongoing military conflicts in Ukraine and Middle East do not have any significant direct effect on the operations. Indirect effects such as increases in energy and transportation costs, increased lead times on components and general cost increases may have some impact on the operations but are deemed to be manageable. If the conflicts spread to more territories, this assessment could change. U.S. is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2023 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

## Other information

### *Forward-looking statements*

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

### **Accounting principles**

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFNR 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2023.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2023 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>  
This Interim Report has not been reviewed by the Group's Auditor.

# Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

## **Dignitana AB**

Corporate Registration Number: 556730-5346

Lund, 21 November 2024

## **Dignitana AB (publ) Board of Directors**

Klas Arildsson  
Chairman of the Board

Lina Karlsson  
Board member

Richard Dilorio  
Board member

Fredrik Lindgren  
Board member

Hope S Rugo  
Board member

## Income Statement- Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2024	Q3 2023	Q1-Q3 2024	Q1-Q3 2023	Full year 2023
<b>Operating Income</b>					
Net sales	22,849	22,219	65,858	64,797	86,063
Capitalized work for own account	0	0	0	0	0
Other operating income	228	126	553	2,312	2,962
<b>Total Operating Income</b>	<b>23,077</b>	<b>22,345</b>	<b>66,411</b>	<b>67,109</b>	<b>89,025</b>
<b>Operating expense</b>					
Goods for Resale	-7,995	-7,167	-21,156	-21,088	-27,092
Operating expense	-4,155	-5,402	-18,856	-18,199	-24,985
Personnel expense	-8,753	-8,840	-31,735	-27,294	-35,988
Depreciation and amortization of tangible and intangible assets	-2,861	-3,828	-10,739	-11,257	-15,112
Other operating expenses	-43	-262	-631	-580	-874
	<b>-23,807</b>	<b>-25,499</b>	<b>-83,117</b>	<b>-78,418</b>	<b>-104,051</b>
<b>Operating profit (loss)</b>	<b>-730</b>	<b>-3,154</b>	<b>-16,706</b>	<b>-11,309</b>	<b>-15,026</b>
<b>Result from financial investments</b>					
Other Interest income and similar items	93	294	973	877	1,109
Interest expenses and similar items	-910	-825	-2,324	-1,853	-3,311
	<b>-817</b>	<b>-531</b>	<b>-1,351</b>	<b>-976</b>	<b>-2,202</b>
<b>Profit after financial items</b>	<b>-1,547</b>	<b>-3,685</b>	<b>-18,057</b>	<b>-12,285</b>	<b>-17,228</b>
<b>Profit before tax</b>	<b>-1,547</b>	<b>-3,685</b>	<b>-18,057</b>	<b>-12,285</b>	<b>-17,228</b>
Tax on profit for the period	0		0	0	-135
<b>Results for the Period</b>	<b>-1,547</b>	<b>-3,685</b>	<b>-18,057</b>	<b>-12,285</b>	<b>-17,363</b>
Average number of shares	80,541,891	70,474,155	76,817,197	70,474,155	70,474,155
<b>Earnings per share, SEK</b>	<b>-0.02</b>	<b>-0.05</b>	<b>-0.24</b>	<b>-0.17</b>	<b>-0.25</b>

## Balance Sheet- Dignitana Group, TSEK

DIGNITANA GROUP	2024-09-30	2023-09-30	2023-12-31
<b>ASSETS</b>			
<b>FIXED ASSETS</b>			
<b>Intangible assets</b>			
Capitalized expenses for development	286	3,723	2,584
	<b>286</b>	<b>3,723</b>	<b>2,584</b>
<b>Tangible assets</b>			
Equipment, tools and installations	102	173	140
Machinery and other technical facilities	24	42	37
Leasing machines	15,246	22,878	19,849
	<b>15,372</b>	<b>23,093</b>	<b>20,026</b>
<b>Financial assets</b>			
Other long term receivables	570	350	409
	<b>570</b>	<b>350</b>	<b>409</b>
<b>Total Fixed Assets</b>	<b>16,228</b>	<b>27,166</b>	<b>23,019</b>
<b>CURRENT ASSETS</b>			
<b>Inventories and similar</b>			
Finished goods and goods for resale	9,925	5,538	7,413
	<b>9,925</b>	<b>5,538</b>	<b>7,413</b>
<b>Current Receivables</b>			
Accounts Receivable	4,023	5,375	4,915
Current Tax Assets	0	0	0
Other Current Receivables	773	552	422
Prepaid expenses and accrued income	2,530	2,779	3,035
	<b>7,326</b>	<b>8,706</b>	<b>8,372</b>
<b>Cash and Bank Balances</b>	<b>4,448</b>	<b>6,961</b>	<b>6,027</b>
<b>Total Current Assets</b>	<b>21,699</b>	<b>21,205</b>	<b>21,812</b>
<b>Total Assets</b>	<b>37,927</b>	<b>48,371</b>	<b>44,831</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share Capital	8,054	7,047	7,047
Unregistered share capital	0	0	0
Ongoing new issue	0	0	0
Other contributed capital	263,825	246,550	246,550
Other equity including profit for the year	-264,310	-240,542	-246,333
<b>Total Equity</b>	<b>7,569</b>	<b>13,055</b>	<b>7,264</b>
<b>Provisions</b>			
Other provisions for pensions and similar obligations	570	350	409
Other provisions	2,670	0	0
	<b>3,240</b>	<b>350</b>	<b>409</b>
<b>Long Term Liabilities</b>			
Other long term liabilities	2,932	7,464	6,077
<b>Total Long Term Liabilities</b>	<b>2,932</b>	<b>7,464</b>	<b>6,077</b>
<b>Current Liabilities</b>			
Liabilities to credit institutions	7,547	11,728	13,027
Accounts payable	9,934	3,165	6,065
Other current liabilities	1,510	6,400	6,598
Accrued expenses and deferred income	5,195	6,209	5,391
<b>Total current liabilities</b>	<b>24,186</b>	<b>27,502</b>	<b>31,081</b>
<b>Total liabilities</b>	<b>27,118</b>	<b>34,966</b>	<b>37,158</b>
<b>Total Equity and Liabilities</b>	<b>37,927</b>	<b>48,371</b>	<b>44,831</b>

## Consolidated Statement of Changes in Equity

- Dignitana Group, TSEK

DIGNITANA GROUP	Share capital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
<b>Opening equity on 1/1/2023</b>	<b>7,047</b>	<b>245,866</b>	<b>-228,663</b>	<b>24,250</b>
Net loss for the period			-12,285	-12,285
Share warrants		684		684
Change in translation difference relating to subsidiaries			406	406
<b>Closing equity on 9/30/2023</b>	<b>7,047</b>	<b>246,550</b>	<b>-240,542</b>	<b>13,055</b>
Net loss for the period			-5,078	-5,078
Share warrants				0
Change in translation difference relating to subsidiaries			-713	-713
<b>Closing equity on 12/31/2023</b>	<b>7,047</b>	<b>246,550</b>	<b>-246,333</b>	<b>7,264</b>
Net loss for the period			-18,057	-18,057
New share issue	1,007	18,122		19,129
Issue costs		-847		-847
Change in translation difference relating to subsidiaries			80	80
<b>Closing equity on 9/30/2024</b>	<b>8,054</b>	<b>263,825</b>	<b>-264,310</b>	<b>7,569</b>

## Statement of Cash Flows- Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2024	Q3 2023	Q1-Q3 2024	Q1-Q3 2023	Full year 2023
<b>Operating activities</b>					
Profit after financial investments	-1,547	-3,685	-18,057	-12,285	-17,228
Adjustments for items not affecting cash flows, etc	2,248	3,526	15,171	11,817	16,835
Tax paid	0	0	0	-16	-16
<b>Cash flow from operating activities before changes in working capital</b>	<b>701</b>	<b>-159</b>	<b>-2,886</b>	<b>-484</b>	<b>-409</b>
<b>Cash flow from changes in working capital</b>					
Change in inventories	3,781	-573	-2,760	-1,370	-3,549
Change in other current receivables	876	1,263	645	1,536	1,407
Change in other current liabilities	-2,004	-704	4,245	-4,961	-3,193
<b>Cash flows from operating activities</b>	<b>3,354</b>	<b>-173</b>	<b>-756</b>	<b>-5,279</b>	<b>-5,744</b>
<b>Investing activities</b>					
Investments in intangible assets	0	0	0	0	0
Proceeds from sale of intangible assets	0	0	0	0	0
Investments in tangible assets	-973	-1,045	-4,442	-3,139	-4,597
Proceeds from sale of tangible assets	0	593	130	593	1,034
Investments in other financial fixed assets	-43	-58	-161	-175	-233
<b>Cash flows from investing activities</b>	<b>-1,016</b>	<b>-510</b>	<b>-4,473</b>	<b>-2,721</b>	<b>-3,796</b>
<b>Financing activities</b>					
New share issue	0	0	13,564	0	0
Issue expenses	-300	0	-847	0	0
Options issued	0	0	0	684	684
New loans	0	5,000	6,054	13,098	22,855
Repaid loans	-4,336	-2,754	-15,039	-7,766	-16,500
<b>Cash flow from financial activities</b>	<b>-4,636</b>	<b>2,246</b>	<b>3,732</b>	<b>6,016</b>	<b>7,039</b>
<b>Cash flow for the period</b>	<b>-2,298</b>	<b>1,563</b>	<b>-1,497</b>	<b>-1,984</b>	<b>-2,501</b>
<b>Cash and cash equivalents at beginning of period</b>					
Cash and cash equivalents at beginning of period	6,977	5,423	6,027	8,869	8,869
<b>Exchange-rate differences in cash and cash equivalents</b>					
Exchange-rate differences in cash and cash equivalents	-231	-25	-82	76	-341
<b>Cash and cash equivalents at end of period</b>	<b>4,448</b>	<b>6,961</b>	<b>4,448</b>	<b>6,961</b>	<b>6,027</b>



## Income Statement- Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	Q3 2024	Q3 2023	Q1-Q3 2024	Q1-Q3 2023	Full year 2023
<b>Operating Income</b>					
Net sales	3,300	3,384	13,243	10,943	14,290
Capitalized work for own account	0	0	0	0	0
Other operating income	212	125	508	2,242	2,870
<b>Total Operating Income</b>	<b>3,512</b>	<b>3,509</b>	<b>13,751</b>	<b>13,185</b>	<b>17,160</b>
<b>Operating expense</b>					
Goods for Resale	-529	-167	-2,686	-2,201	-2,516
Operating expense	-1,573	-1,966	-6,488	-6,142	-10,462
Personnel expense	-3,741	-3,651	-16,509	-12,212	-16,245
Depreciation and amortization of tangible and intangible assets	-31	-1,154	-2,340	-3,462	-4,617
Other operating expenses	-70	-262	-637	-579	-734
	<b>-5,944</b>	<b>-7,200</b>	<b>-28,660</b>	<b>-24,596</b>	<b>-34,574</b>
<b>Operating profit (loss)</b>	<b>-2,432</b>	<b>-3,691</b>	<b>-14,909</b>	<b>-11,411</b>	<b>-17,414</b>
<b>Result from financial investments</b>					
Other Interest income and similar items	93	293	973	876	1,912
Interest expenses and similar items	-679	-521	-1,540	-866	-2,120
	<b>-586</b>	<b>-228</b>	<b>-567</b>	<b>10</b>	<b>-208</b>
<b>Profit after financial items</b>	<b>-3,018</b>	<b>-3,919</b>	<b>-15,476</b>	<b>-11,401</b>	<b>-17,622</b>
<b>Profit before tax</b>	<b>-3,018</b>	<b>-3,919</b>	<b>-15,476</b>	<b>-11,401</b>	<b>-17,622</b>
Tax on profit for the period	0	0	0	0	0
<b>Results for the Period</b>	<b>-3,018</b>	<b>-3,919</b>	<b>-15,476</b>	<b>-11,401</b>	<b>-17,622</b>

# Balance Sheet- Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2024-09-30	2023-09-30	2023-12-31
<b>ASSETS</b>			
<b>FIXED ASSETS</b>			
<b>Intangible assets</b>			
Capitalized expenses for development	266	3,702	2,564
	<b>266</b>	<b>3,702</b>	<b>2,564</b>
<b>Tangible assets</b>			
Equipment, tools and installations	36	46	44
Other machinery and other technical facilities	24	42	37
Leasing machines	0	31	22
	<b>60</b>	<b>119</b>	<b>103</b>
<b>Financial assets</b>			
Participations in group companies	66,198	66,198	66,198
Receivable from group companies	8,327	8,944	8,284
Other long term receivables	570	350	409
	<b>75,095</b>	<b>75,492</b>	<b>74,891</b>
<b>Total Fixed Assets</b>	<b>75,421</b>	<b>79,313</b>	<b>77,558</b>
<b>CURRENT ASSETS</b>			
<b>Inventories and similar</b>			
Finished goods and goods for resale	3,334	2,339	3,265
	<b>3,334</b>	<b>2,339</b>	<b>3,265</b>
<b>Current Receivables</b>			
Accounts Receivable	735	1,074	549
Receivables from group companies	990	1,593	1,376
Current Tax Assets	0	0	0
Other Current Receivables	381	360	332
Prepaid expenses and accrued income	670	699	893
	<b>2,776</b>	<b>3,726</b>	<b>3,150</b>
<b>Cash and Bank Balances</b>	<b>673</b>	<b>2,237</b>	<b>899</b>
<b>Total Current Assets</b>	<b>6,783</b>	<b>8,302</b>	<b>7,314</b>
<b>Total Assets</b>	<b>82,204</b>	<b>87,615</b>	<b>84,872</b>

# Balance Sheet- Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2024-09-30	2023-09-30	2023-12-31
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
<b>Restricted equity</b>			
Share Capital	8,054	7,047	7,047
Unregistered share capital	0	0	0
Fund for development expenses	266	3,702	2,564
	<b>8,320</b>	<b>10,749</b>	<b>9,611</b>
<b>Non-restricted equity</b>			
Share premium reserves	263,825	246,550	246,550
Other non-restricted equity	-189,448	-175,261	-174,123
Results for the period	-15,476	-11,401	-17,622
	<b>58,901</b>	<b>59,888</b>	<b>54,805</b>
<b>Total Equity</b>	<b>67,221</b>	<b>70,637</b>	<b>64,416</b>
<b>Provisions</b>			
Other provisions for pensions and similar obligations	570	350	409
Other provisions	2,671	0	0
	<b>3,241</b>	<b>350</b>	<b>409</b>
<b>Long Term Liabilities</b>			
Other long term liabilities	1,598	5,000	2,848
<b>Total Long Term Liabilities</b>	<b>1,598</b>	<b>5,000</b>	<b>2,848</b>
<b>Current Liabilities</b>			
Liabilities to credit institutions	1,666	0	1,805
Accounts payable	1,422	809	849
Current payable to group company	2,513	636	4,588
Other current liabilities	1,297	6,034	6,110
Accrued expenses and deferred income	3,246	4,149	3,847
<b>Total current liabilities</b>	<b>10,144</b>	<b>11,628</b>	<b>17,199</b>
<b>Total liabilities</b>	<b>10,144</b>	<b>11,628</b>	<b>17,199</b>
<b>Total Equity and Liabilities</b>	<b>82,204</b>	<b>87,615</b>	<b>84,872</b>

## Financial calendar

<b>20 Feb 2025</b>	2024 Year End Report
<b>2 May 2025</b>	Annual Report
<b>22 May 2025</b>	Q1 Report
<b>22 May 2025</b>	Annual General Meeting
<b>21 Aug 2025</b>	Q2 Report
<b>20 Nov 2025</b>	Q3 Report

All financial reports are available at  
[www.dignitana.com/investor-relations/financial-reports/](http://www.dignitana.com/investor-relations/financial-reports/)

## Contact information

### **Dignitana AB**

Traktorgränden 3, 226 60 Lund  
+46 (0) 46-16 30 90  
info@dignitana.com  
investorrelations@dignitana.com  
www.dignitana.com

### **Certified Adviser**

Redeye AB  
+46 8 121 576 90  
certifiedadviser@redeye.se  
www.redeye.se